Breast Cancer
Conditions
Keywords
FTD/TPI, TAS-102, Trifluridine
Brief summary
This is a single arm, open-label, lead in phase Ib dose confirmation, followed by phase II study with 2 parallel study cohorts.
Detailed description
Phase Ib Patients will be treated with twice-daily dosing of FTD/TPI in a 3+3 dose escalation design Phase II Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal. 2 parallel cohorts of patients will be enrolled : Cohort A : patients with prior exposure to fluoropyrimidines Cohort B : patients without prior exposure to fluoropyrimidines
Interventions
Sponsors
National University Hospital, Singapore
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
2 parallel cohorts of patients will be enrolled : Cohort A : patients with prior exposure to fluoropyrimidines Cohort B : patients without prior exposure to fluoropyrimidines
Eligibility
Sex/Gender
ALL
Age
21 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 21 years. * Histological or cytological diagnosis of breast carcinoma. * ECOG 0-2. * HER2 negative tumor (IHC 0 -1+ or IHC 2+ and confirmed on HER2 FISH to be negative based on histological report). * Patients with HER2 positive tumor may be enrolled if they have failed at least two lines of anti-HER2 based therapies in the metastatic setting, or are intolerant to trastuzumab * Any hormone receptor status. * Any number of lines of prior palliative endocrine therapy for patients with hormone receptor positive cancer. * Has measureable or evaluable disease based on RECIST 1.1 criteria * Estimated life expectancy of at least 12 weeks. * Has documented progressive disease from last line of therapy. * Has recovered from acute toxicities from prior anti-cancer therapies * Adequate organ function including the following: oBone marrow: (I) Absolute neutrophil (segmented and bands) count (ANC) ≥1.5 x 109/L (ii) Platelets ≥100 x 109/L (ii) Hemoglobin ≥8 x 109/L oHepatic: (I)Bilirubin ≤ 1.5 x upper limit of normal (ULN), (ii)ALT or AST ≤ 2.5x ULN, (or ≤ 5 X with liver metastases) oRenal: (I) Creatinine ≤1.5x ULN * Signed informed consent from patient or legal representative. * Able to comply with study-related procedures. * Prior therapy (patients enrolled in phase Ib may be enrolled if they fulfil prior therapy criteria for either Cohort A or Cohort B) * Cohort A only: Has received at least 2 lines of palliative systemic therapy, including prior fluropyrimidines (capecitabine, TS-1 or 5-fluorouracil) in the palliative setting, or in the adjuvant setting; patients who have only prior exposure to adjuvant fluoropyrimidines must have relapsed within 12 months of completing adjuvant fluoropyrimidines * Cohort B only: Any number of prior lines of palliative chemotherapy and has not received fluoropyrimidines (capecitabine, TS-1 or 5-fluorouracil) in the palliative setting or in the adjuvant setting; patients who have prior exposure to adjuvant fluoropyrimidines are eligible if they have relapsed 12 months from completion of adjuvant fluoropyrimidines.
Exclusion criteria
* Treatment within the last 30 days with any investigational drug. * Concurrent administration of any other tumour therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy. * Major surgery within 28 days of study drug administration. * Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy. * Pregnancy. * Breast feeding. * Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator. * Active bleeding disorder or bleeding site. * Non-healing wound. * Poorly controlled diabetes mellitus. * Second primary malignancy that is clinically detectable at the time of consideration for study enrollment. * Symptomatic brain metastasis. * History of significant neurological or mental disorder, including seizures or dementia. * Unable to comply with study procedures Phase Ib lead-in can recruit patients who fulfil criteria for either Cohort A or Cohort B AND all other inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | 4 months | Primary endpoint is proportion of patients who are PFS at 4 months in Cohort A |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response | 5 years | The death of any patient in the trial from any cause will be recorded and the amount of time from enrollment in the trial until death will be recorded in weeks. |
| Progression Free Survival (PFS) | 6 months | Proportion of patients who are PFS at 6 months in Cohort B |
| Safety and Efficacy | 5 years | All adverse events experienced by all patients (in both cohort , RP2D of FTD/TPI in MBC Patients) exposed to Trifluridine/tipiracil will be recorded and graded according to CTCAE version 5. |
Countries
Singapore
Outcome results
None listed